ÂÜÀòÂÒÂ×

Peter Reed is a seasoned executive with extensive experience in market access, reimbursement, and commercial strategy within the pharmaceutical industry. Currently serving as Vice President at Vanda Pharmaceuticals since March 2014, Peter leads the pre-launch and launch commercialization strategy for the orphan drug Hetlioz, focusing on patient, provider, and payer access, reimbursement, and pricing. Prior roles include National Account Executive at Orexo US, Inc., and Corporate Account/National Account Executive at Endo Pharmaceuticals, where Peter developed market access strategies in various healthcare segments. An independent consultant in 2010, Peter also held positions with Strativa Pharmaceuticals and Schering-Plough Pharmaceuticals, where Peter was responsible for managed markets efforts and product reimbursement strategies. Peter holds an MBA in Strategy and Finance from Babson F.W. Olin Graduate School of Business and a BIS in Business and Health Care from George Mason University.